Abstract
Eosinophilic gastroenteritis (EG) is a rare disorder characterized by eosinophilic infiltration of the gastrointestinal tract. No medication at present is approved by the Food and drug administration of United States for the treatment of EG. The rarity of the disease limits our experience with the different management options. It also limits the ability to conduct randomized controlled trials that could clearly delineate the efficacy of new therapeutic agents. This review assesses the various management options that have been tried on patients with EG.
Acknowledgement
Nancy Gupta, Arun Aggarwal, Rahul Gupta, Sachin Sule and David C. Wolf: Conception, design, and participated in writing the manuscript. David C. Wolf: Final approval of the manuscript. The results presented in this paper have not been published previously in whole or part. The study was not funded from any outside sponsor or funding agency.
Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.